C F Samer

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. pmc Applications of CYP450 testing in the clinical setting
    C F Samer
    Clinical Pharmacology and Toxicology, Geneva University Hospitals, Rue Gabrielle Perret Gentil 4, 1211, Geneva, Switzerland
    Mol Diagn Ther 17:165-84. 2013
  2. ncbi request reprint [Genetic polymorphism and drug interactions: their importance in the treatment of pain]
    Caroline F Samer
    Service de pharmacologie et toxicologie cliniques et Centre multidisciplinaire d ├ętude et de traitement de la douleur, Hopitaux Universitaires de Geneve, Geneve, Suisse
    Can J Anaesth 52:806-21. 2005
  3. pmc The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone
    C F Samer
    Clinical Pharmacology and Toxicology and Multidisciplinary Pain Centre, Department of Anaesthesiology, Pharmacology and Intensive Care, Geneva University Hospitals, Switzerland
    Br J Pharmacol 160:907-18. 2010
  4. pmc Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety
    C F Samer
    Clinical Pharmacology and Toxicology and Multidisciplinary Pain Centre, Department of Anaesthesiology, Pharmacology and Intensive Care, Geneva University Hospitals, Geneva, Switzerland
    Br J Pharmacol 160:919-30. 2010

Detail Information

Publications4

  1. pmc Applications of CYP450 testing in the clinical setting
    C F Samer
    Clinical Pharmacology and Toxicology, Geneva University Hospitals, Rue Gabrielle Perret Gentil 4, 1211, Geneva, Switzerland
    Mol Diagn Ther 17:165-84. 2013
    ..Genotyping and phenotyping may therefore be considered where dosing guidelines according to CYP genotype have been published, and help identify the right molecule for the right patient...
  2. ncbi request reprint [Genetic polymorphism and drug interactions: their importance in the treatment of pain]
    Caroline F Samer
    Service de pharmacologie et toxicologie cliniques et Centre multidisciplinaire d ├ętude et de traitement de la douleur, Hopitaux Universitaires de Geneve, Geneve, Suisse
    Can J Anaesth 52:806-21. 2005
    ..To evaluate the impact of certain genetic polymorphisms on variable responses to analgesics..
  3. pmc The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone
    C F Samer
    Clinical Pharmacology and Toxicology and Multidisciplinary Pain Centre, Department of Anaesthesiology, Pharmacology and Intensive Care, Geneva University Hospitals, Switzerland
    Br J Pharmacol 160:907-18. 2010
    ..The effects of CYP2D6 and/or CYP3A activity modulation on the pharmacokinetics of oxycodone remains poorly explored...
  4. pmc Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety
    C F Samer
    Clinical Pharmacology and Toxicology and Multidisciplinary Pain Centre, Department of Anaesthesiology, Pharmacology and Intensive Care, Geneva University Hospitals, Geneva, Switzerland
    Br J Pharmacol 160:919-30. 2010
    ..The possible role of an active metabolite in the pharmacodynamics of oxycodone has been questioned and the importance of CYP3A-mediated effects on the pharmacokinetics and pharmacodynamics of oxycodone has been poorly explored...